Research has demonstrated that SGLT2 inhibitors can serve as a potential therapeutic strategy for preventing CI-AKI, owing to their inhibitory effects on the HIF-1α/HE4/NF-κB pathway (Huang et al., 2022). This evidence concerns the gene NFKB1 and acute kidney injury.